The first quarter of 2012 is marked by a decline in profits of almost 40%. Under Brennan, Astra Zeneca was one of the big pharma companies hardest hit by generic competition. Now the hot potato passes to the successor Louis Schweitzer. Read everything:
Bad sales of AstraZeneca and CEO Brennan leaves
source: Finance and Markets 27/04/2012
